Gilead Sciences (GILD)
Latest
-
Stock Market Today: Stocks Build on Broad-Based Gains
A heavy week of earnings and data ahead couldn't spoil the market's record-setting Monday mood.
By Dan Burrows Published
-
How to Find the Best Biotech ETFs
ETFs The best biotech ETFs allow investors a diversified way to play the volatile biotechnology industry. Here's how to find them.
By Coryanne Hicks Last updated
ETFs -
9 Big Pharmaceutical Stocks Sporting Stellar Yields
healthcare stocks Large-cap pharmaceutical stocks offer investors stable, substantial dividends, regardless of market conditions. Here are nine that stand out.
By Jeff Reeves Published
healthcare stocks -
5 High-Yield Dividend Stocks for Healthy Income
dividend stocks The healthcare sector is chock-full of safe, sturdy income plays. But these five top-rated high-yield dividend stocks really stand out in the crowd.
By David Cohne Published
dividend stocks -
Stock Market Today 10/22/20: Stimulus' Siren Song Pulls the Bulls Along
stocks Thursday's gains were driven by more positive language on stimulus negotiations, but an uncertain timeline kept those advances modest.
By Kyle Woodley Published
stocks -
Stock Market Today 9/14/20: Big Deal! Stocks Solidly in the Black on 'M&A Monday'
Markets Big dealmaking from Nvidia (NVDA) and Gilead Sciences (GILD), as well as renewed COVID vaccine hopes, sent a jolt into stocks Monday.
By Kyle Woodley Published
Markets -
Closing Bell 7/13/20: This Is Your Market on (Coronavirus) Drugs
Markets A rapid rally to start the week, sparked by encouraging vaccine news from Pfizer and BioNTech, collapsed in the afternoon.
By Kyle Woodley Published
Markets -
Closing Bell 7/10/20: Gilead Gives Stocks a Booster Shot
Markets Stocks rallied out of negative territory Friday after Gilead announced that remdesivir helped reduce COVID-19 mortality risk in a clinical trial.
By Kyle Woodley Published
Markets -
Gilead Sciences' (GILD) Remdesivir Sparks Market Hope With Trial Success
investing Gilead's COVID-19 treatment shows efficacy in Phase 3 trial, NIAID study
By Kyle Woodley Published
investing